T.T.M. Lee, C. Collett, S. Bergford, S. Hartnell, H. R. Murphy, E. Scott, R. S. Lindsay, K. F. Hunt, D. R. McCance, K. Barnard-Kelly, D. Rankin, J. Lawton, R. Reynolds, E. Flanagan, M. Hammond, L. Shepstone, M. Wilinska, J. Sibayan, C. Kollman, R. Beck, R. Hovorka
{"title":"Automated Insulin Delivery in Women With Pregnancy Complicated by Type 1 Diabetes","authors":"T.T.M. Lee, C. Collett, S. Bergford, S. Hartnell, H. R. Murphy, E. Scott, R. S. Lindsay, K. F. Hunt, D. R. McCance, K. Barnard-Kelly, D. Rankin, J. Lawton, R. Reynolds, E. Flanagan, M. Hammond, L. Shepstone, M. Wilinska, J. Sibayan, C. Kollman, R. Beck, R. Hovorka","doi":"10.1097/01.aoa.0001016092.68961.48","DOIUrl":null,"url":null,"abstract":"(N Engl J Med. 2023;389:1566–1578)\n Type 1 diabetes often causes significant complications both during pregnancy and immediately after delivery for both mother and infant. This makes glycemic control during pregnancy for these women of utmost importance for their health and that of their baby. Several therapies have been introduced for pregnancies complicated by type 1 diabetes, and one that is relatively new is hybrid closed loop therapy; because of its recent development, the efficacy of this treatment is still unclear. This study was designed to test if the initiation of hybrid closed loop therapy before 16 weeks of gestation would improve glucose levels during pregnancy. The primary outcome for this study was the percentage of time that glucose levels were within the pregnancy-specific target range of 63 to 140 mg per deciliter.","PeriodicalId":19432,"journal":{"name":"Obstetric Anesthesia Digest","volume":"65 17","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetric Anesthesia Digest","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.aoa.0001016092.68961.48","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
(N Engl J Med. 2023;389:1566–1578)
Type 1 diabetes often causes significant complications both during pregnancy and immediately after delivery for both mother and infant. This makes glycemic control during pregnancy for these women of utmost importance for their health and that of their baby. Several therapies have been introduced for pregnancies complicated by type 1 diabetes, and one that is relatively new is hybrid closed loop therapy; because of its recent development, the efficacy of this treatment is still unclear. This study was designed to test if the initiation of hybrid closed loop therapy before 16 weeks of gestation would improve glucose levels during pregnancy. The primary outcome for this study was the percentage of time that glucose levels were within the pregnancy-specific target range of 63 to 140 mg per deciliter.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
